Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, Starts Phase II Clinical Study HEART","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Valbiotis"},{"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Authorized to Launch HEART for TOTUM-070 to treat High Blood LDL-Cholesterol Levels","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Valbiotis"},{"company":"Sanofi","sponsor":"Rancho Santa Fe Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM\u2022070, Against Hypercholesterolemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Valbiotis"}]

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat

Details:

This agreement provides RSF Bio with Sanofi’s rights to Ataciguat. With this license, RSF Bio will have the rights it needs to continue development of Ataciguat through clinical trials in the United States and potentially in select international countries.

Lead Product(s): Ataciguat

Therapeutic Area: Cardiology/Vascular Diseases Product Name: HMR1766

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Rancho Santa Fe Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement June 17, 2021

Sanofi Company Banner

18th Oligonucleotide Therapeutics

Not Confirmed

envelop

Contact Supplier

Valbiotis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia

Details:

This innovative study is the first to characterize the metabolites of TOTUM•070 in humans and their mode of action in the liver in a population of 10 healthy volunteers. TOTUM•070 was tested at its clinical daily dose (5g), used also in the Phase II HEART clinical trial.

Lead Product(s): Totum•070

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Totum•070

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 29, 2022

ASK
US

Upload
your Pipeline Activity

Valbiotis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Valbiotis Authorized to Launch HEART for TOTUM-070 to treat High Blood LDL-Cholesterol Levels

Details:

The main objective of this clinical study is to evaluate the efficacy of a 5g daily dose of TOTUM-070 and to confirm its safety. HEART results will support the application for a proprietary health claim related to the reduction of LDL-cholesterol.

Lead Product(s): TOTUM-070

Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-070

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 15, 2021

ASK
US

Upload
your Pipeline Activity

Valbiotis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, Starts Phase II Clinical Study HEART

Details:

The clinical study HEART on TOTUM-070, a Phase II randomized placebo-controlled and double blind study, has just been initiated in accordance with the road map, the study protocol having been submitted to the French health authorities.

Lead Product(s): TOTUM-070

Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-070

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 27, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY